1
|
Ricketts K, Ahmad R, Beaton L, Cousins B, Critchley K, Davies M, Evans S, Fenuyi I, Gavriilidis A, Harmer QJ, Jayne D, Jefford M, Loizidou M, Macrobert A, Moorcroft S, Naasani I, Ong ZY, Prise KM, Rannard S, Richards T, Schettino G, Sharma RA, Tillement O, Wakefield G, Williams NR, Yaghini E, Royle G. Recommendations for clinical translation of nanoparticle-enhanced radiotherapy. Br J Radiol 2018; 91:20180325. [PMID: 30179039 PMCID: PMC6319829 DOI: 10.1259/bjr.20180325] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 08/23/2018] [Accepted: 08/29/2018] [Indexed: 01/06/2023] Open
Abstract
A multi-disciplinary cooperative for nanoparticle-enhanced radiotherapy (NERT) has been formed to review the current status of the field and identify key stages towards translation. Supported by the Colorectal Cancer Healthcare Technologies Cooperative, the cooperative comprises a diverse cohort of key contributors along the translation pathway including academics of physics, cancer and radio-biology, chemistry, nanotechnology and clinical trials, clinicians, manufacturers, industry, standards laboratories, policy makers and patients. Our aim was to leverage our combined expertise to devise solutions towards a roadmap for translation and commercialisation of NERT, in order to focus research in the direction of clinical implementation, and streamline the critical pathway from basic science to the clinic. A recent meeting of the group identified barriers to and strategies for accelerated clinical translation. This commentary reports the cooperative's recommendations. Particular emphasis was given to more standardised and cohesive research methods, models and outputs, and reprioritised research drivers including patient quality of life following treatment. Nanoparticle design criteria were outlined to incorporate scalability of manufacture, understanding and optimisation of biological mechanisms of enhancement and in vivo fate of nanoparticles, as well as existing design criteria for physical and chemical enhancement. In addition, the group aims to establish a long-term and widespread international community to disseminate key findings and create a much-needed cohesive body of evidence necessary for commercial and clinical translation.
Collapse
Affiliation(s)
- Kate Ricketts
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Reem Ahmad
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Laura Beaton
- NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London, UK
| | - Brian Cousins
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Kevin Critchley
- School of Physics and Astronomy, University of Leeds, Leeds, UK
| | | | - Stephen Evans
- School of Physics and Astronomy, University of Leeds, Leeds, UK
| | - Ifeyemi Fenuyi
- Division of Surgery and Interventional Science, University College London, London, UK
| | | | | | - David Jayne
- Leeds Institute of Clinical Sciences, St James’s University Hospital, Leeds, UK
| | | | - Marilena Loizidou
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Alexander Macrobert
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Sam Moorcroft
- School of Physics and Astronomy, University of Leeds, Leeds, UK
| | | | | | - Kevin M Prise
- Centre for Cancer Research & Cell Biology, Queens University Belfast, Belfast, UK
| | - Steve Rannard
- Department of Chemistry and Materials Innovation Factory, University of Liverpool, Liverpool, UK
| | - Thomas Richards
- Department of Oncology, University College London Hospital NHS Foundation Trust, London, UK
| | - Giuseppe Schettino
- Medical Radiation Science Group, National Physical Laboratory, Teddington, UK
| | - Ricky A Sharma
- NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London, UK
| | | | | | - Norman R Williams
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Elnaz Yaghini
- Division of Surgery and Interventional Science, University College London, London, UK
| | - Gary Royle
- Department of Medical Physics and Bioengineering, University College London, London, UK
| |
Collapse
|